Introduction
health care has two ultimate goals, which are to prolong the life and to increase the quality of life. Measuring the health related quality of life gives important information about the health care progress. the chronic kidney disease affects more and more people in recent years and the need for transplantation increases (6). Worldwide there are 1.1 million patients registered in end-stage chronic kidney disease and their number increases with 7% per year. the prevalence of the disease is 135 per million inhabitants in europe and 336 in the USA and increases permanently mainly as a result of diabetes progress. the survival after kidney transplantation is from 88% to 95% in the case when a dead or living donor is used, respectively (1) . there are studies showing that the quality of life of patents with chronic kidney disease is severely hampered, but what happens after the kidney transplantation is relatively rarely studied (9) . the goal of our study was to analyze the cost of pharmacotherapy and quality of life of patents after kidney transplantation compared to those of patients with chronic kidney disease in Bulgaria.
Materials and Methods
A retrospective pharmacotherapy cost study and prospective health related quality of life study was performed during 2010 -2011 at the biggest Sofia hospital serving all transplant patients. the cost of pharmacotherapy was analyzed after reviewing records of all patients with chronic kidney disease and kidney transplantation. Mean cost per month was calculated for both diagnoses.
the health related quality of life (qol) was evaluated with the multidimensional questionnaire SF-36. the SF-36 is a self administered questionnaire containing 36 items. it measures health on eight multi-item dimensions covering physical functioning, role limitations, bodily pain, social functioning, general mental health, role limitations due to emotional problems, vitality, energy or fatigue, general health perceptions. there is also health state self evaluation in comparison with the previous year. For each dimension, item scores are coded, summed, and transformed on to a scale from 0 (worst health) to 100 (best health) (7) . the SF-36 was previously used and validated for Bulgaria for patients with chronic kidney disease (9) . Sixty-two transplant and 19 patients with chronic kidney diseases were interviewed.
Descriptive statistics, one way AnoVA analysis, Spearman correlation, and Kruskal-Wallis analysis were performed to evaluate the statistical significance of the differences in the QoL results and discussion pharmacotherapy cost All the studied patients with chronic kidney disease were on hemodialysis and their pharmacotherapy included antianemic and blood formulating medicines. After the transplantation the therapy comprises mostly of immunosuppressors ( Table 1) . fig. 1) . This difference was statistically significant in comparison with transplant patients (AnoVA, P < 0.05) - Table 3 and Table 4 . it might be supposed that the necessity of frequent hemodialysis significantly limits the everyday life. in both diagnoses the mean quality of life is lower than the maximum possible 100 points in all domains ( fig. 1) . Patients with chronic kidney diseases are with lower qol in all domains in comparison with transplanted patients. the differences in the quality of life are statistically significant (ANOVA, P = 0.0076). the higher mean values of the qol in patients with kidney transplantation are probably due to the fact that the successful transplantations ensure normal life.
We found a correlation between the mean cost of pharmacotherapy and the mean qol in the patients with kidney transplantation but not in the group with chronic kidney disease. the correlation is positive which means that the increase in the cost of pharmacotherapy should lead to increased qol of patients ( Table 5) . the lack of correlation in the second group of patients could be commented with the final stage of the chronic kidney disease where little could be done to improve the quality of life. the correlation between the characteristics of patients and particular domains of the qol were further evaluated with Spearman test (Table 6 and Table 7 ). in the group of patients with kidney transplantation the place of living and general health state were correlated positively and people living in the towns were shown to have better quality of life, probably due to the fact that they are closer to the health care services (Table  6) . the cost of pharmacotherapy and health state in comparison with the previous year was also positively correlated, so with the increase of the cost the health care state self-evaluation improves.
in patients with chronic kidney disease the cost of pharmacotherapy and general health state were positively associated and the increase in the cost of therapy was found to benefit the patients' general health state evaluation, as well as to diminish the pain ( Table 7) . the kidney transplantation is the only cure for chronic kidney disease. it aims to increase the patients' life expectancy through optimal kidney functioning. A variety of factors could influence the success of the transplantation and among them are the compatibility among the donor and recipient, immunological status, age, availability of infections, surgical complications, quality of life before the transplantation etc. (8) . in this sense the studies of the quality of life of transplanted patients are important for the evaluation of the success of transplantation and its impact on the daily life (7).
After its development in 1980 the SF-36 became one of the most often used multidimensional instruments for qol measurement (3, 5) . the use of SF-36 in our study was also based on the previous experience gained with the patients with chronic kidney disease in Bulgaria (9) . Our study confirmed the results of the previous one that the chronic kidney disease severely hampers the quality of life. It also confirmed the results of other studies that the psychological well-being is affected worst (2) . Some new evidence is added for the significant influence of the transplantation on the QoL. In addition the study reveals that the access to health care and higher spending on pharmaceuticals also influences positively the QoL of transplant patients. the cost of therapy as an important qol determinant was also confirmed (4) .
our study has some limitation as is the fact that it is not a long-term analysis but just a shot of the current state of the art. Further inquiries should be done to evaluate the long-term qol after the transplantation.
conclusions
This is the first Bulgarian study of the quality of life of kidney transplant patients. it shows that the SF-36 could be successfully used in this group of patients as well as for comparison with the qol of patients with chronic kidney disease.
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